Back to News
Market Impact: 0.35
Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision
Source: marketbeat.com
Healthcare & BiotechRegulation & LegislationCorporate Guidance & Outlook
Clene (NASDAQ: CLNN) plans to submit a new drug application to the FDA in early Q4 for CNM-Au8, its investigational treatment for amyotrophic lateral sclerosis (ALS). The planned filing is a regulatory milestone that could materially affect the company’s valuation, although approval remains uncertain.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CLNN0.55
More News
- Mark Ruffalo says Paramount’s $111 billion Warner Bros. deal ‘Will stifle creativity, weaken free speech, and cost people their jobs’
- States, cities sue U.S. agencies over weaker vehicle fuel economy rules
- Anthropic warns government attitudes may hurt customer ties, IPO prospectus shows: Reuters
- Paramount and Warner Bros Discovery to become Skydance
- FAA says Boeing 737 Max software glitch not a flight-safety issue
- Paramount’s Warner Bros. megamerger will just be called Skydance